CD38 and Miyoshi myopathy: Although advanced therapeutic strategies such as immunomodulatory drugs, proteasome inhibitors, CD38 monoclonal antibodies, and chimeric antigens receptor-T cell therapy have greatly prolonged the overall survival of patients with MM, MM remains incurable, and almost all patients will eventually relapse.